GANX
Price:
$1.84
Market Cap:
$48.81M
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded...[Read more]
Industry
Biotechnology
IPO Date
2021-03-19
Stock Exchange
NASDAQ
Ticker
GANX
According to Gain Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.72. This represents a change of -33.76% compared to the average of -2.60 of the last 4 quarters.
The mean historical PE Ratio of Gain Therapeutics, Inc. over the last ten years is -27.53. The current -1.72 PE Ratio has changed 524.74% with respect to the historical average. Over the past ten years (40 quarters), GANX's PE Ratio was at its highest in in the June 2024 quarter at -0.66. The PE Ratio was at its lowest in in the March 2018 quarter at -49.33.
Average
-27.53
Median
-20.58
Minimum
-60.64
Maximum
-1.91
Discovering the peaks and valleys of Gain Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.15%
Maximum Annual PE Ratio = -1.91
Minimum Annual Increase = -89.31%
Minimum Annual PE Ratio = -60.64
Year | PE Ratio | Change |
---|---|---|
2023 | -1.91 | -9.64% |
2022 | -2.11 | -46.79% |
2021 | -3.97 | -89.31% |
2020 | -37.18 | -38.69% |
2019 | -60.64 | 2.15% |
The current PE Ratio of Gain Therapeutics, Inc. (GANX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.67
5-year avg
-21.16
10-year avg
-27.53
Gain Therapeutics, Inc.’s PE Ratio is less than BioVie Inc. (-0.67), less than IN8bio, Inc. (-0.45), greater than NewAmsterdam Pharma Company N.V. (-9.03), less than Cue Biopharma, Inc. (-1.18), less than TFF Pharmaceuticals, Inc. (-0.07), greater than aTyr Pharma, Inc. (-2.33), greater than Lantern Pharma Inc. (-2.16), less than Eliem Therapeutics, Inc. (0), greater than Inhibrx Biosciences, Inc. (-2.42), less than Merrimack Pharmaceuticals, Inc. (0.14), greater than Celcuity Inc. (-8.92), greater than Enliven Therapeutics, Inc. (-5.79), greater than Molecular Partners AG (-13.43), greater than MediciNova, Inc. (-2.76), less than Anebulo Pharmaceuticals, Inc. (-0.04), greater than Champions Oncology, Inc. (-5.07), greater than Cyteir Therapeutics, Inc. (-17.21), greater than null (-9.12),
Company | PE Ratio | Market cap |
---|---|---|
-0.67 | $49.22M | |
-0.45 | $21.83M | |
-9.03 | $1.69B | |
-1.18 | $65.25M | |
-0.07 | $1.39M | |
-2.33 | $131.12M | |
-2.16 | $41.31M | |
0 | $342.68M | |
-2.42 | $218.59M | |
0.14 | $223.97M | |
-8.92 | $471.92M | |
-5.79 | $1.16B | |
-13.43 | $214.91M | |
-2.76 | $110.84M | |
-0.04 | $40.20M | |
-5.07 | $58.45M | |
-17.21 | $108.71M | |
-9.12 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gain Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gain Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Gain Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Gain Therapeutics, Inc. (GANX)?
What is the highest PE Ratio for Gain Therapeutics, Inc. (GANX)?
What is the 3-year average PE Ratio for Gain Therapeutics, Inc. (GANX)?
What is the 5-year average PE Ratio for Gain Therapeutics, Inc. (GANX)?
How does the current PE Ratio for Gain Therapeutics, Inc. (GANX) compare to its historical average?